SOSV

InnSight Technology is a biotechnology company focused on advancing the diagnostics and evaluation of eye diseases. The company specializes in developing innovative ophthalmic devices, including a novel, hand-held biosensor designed for the detection of anterior ophthalmic injuries. Additionally, InnSight Technology works on the development of nanotechnology-based medical devices aimed at addressing various clinical needs in ophthalmology. By providing these advanced tools, the company enables clinicians to enhance ocular care and improve patient outcomes in eye health.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Ostoform is a Dublin, Ireland-based medical device company focused on ostomy skin health. It develops patented devices designed to manage skin complications for ostomy patients, including OSTOFORM, a mouldable seal that wraps around the stoma, and FLOWASSIST, which directs stoma output away from the skin. The technology is designed to prevent skin contact with corrosive output, reduce leakage, and improve skin health. The business originated as a spin-out from the University of Limerick and was established in 2016, leveraging patented technology to scale its solutions globally.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Proton Intelligence develops a wearable device that monitors potassium levels in real-time via interstitial fluid, closely correlated to blood. This enables clinicians and patients to manage medications and diets effectively for improved heart and kidney care, particularly targeting hyperkalemia in chronic kidney disease patients with co-morbidities.

Serene Sleep is a medical technology company that focuses on improving sleep quality by addressing snoring and sleep apnea. It develops and offers a non-invasive, targeted treatment procedure using palatal implants, designed to reduce disruptive snoring and enhance overall sleep for both the individual and their partner.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

Founded in 2014, Machine Medicine Technologies develops an AI-powered platform for objective measurement of movement disorders like Parkinson's disease. Using computer vision and pose estimation techniques, it tracks patient movements to provide secure, accessible, and affordable metrics for researchers and healthcare providers.

Exosomm is an innovative foodtech start-up focused on developing nutritional solutions derived from natural milk exosomes. The company was founded based on research from Hadassah Medical Center, led by Prof. Reif's team. Exosomm's flagship product is a specialized food formula designed for patients suffering from inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. This product utilizes a patented active anti-inflammatory ingredient sourced from milk exosomes, which are isolated using a natural and environmentally friendly process. By targeting health and immunity, Exosomm aims to provide effective solutions for individuals with specific dietary needs.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

DisperseBio is a Biotechnology Research firm developing a mechanism to counter microbial contamination on natural surfaces like human body.

Minutia is a biotechnology company focused on developing innovative stem cell-derived transplants aimed at treating Type 1 Diabetes. The company specializes in creating insulin-producing cell transplants that incorporate proprietary nanosensors, allowing for real-time monitoring of transplant status. These immune-evasive cells are designed for subcutaneous implantation, addressing common challenges associated with transplant procedures. By advancing this technology, Minutia seeks to transform the clinical landscape for diabetes management and cell replacement therapies, ultimately working towards a functional cure for this condition.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Asta Bio is a biotechnology company specializing in the development of radiotherapeutics for cancer treatment. It focuses on combining the alpha-emitting radioisotope 211-Astatine with multivalent single-domain antibodies to deliver targeted alpha radiation to tumor cells, sparing healthy cells. This approach aims to effectively destroy cancer cells by breaking their DNA strands.

Tinkeso Therapeutics is a biotechnology company specializing in the development of innovative, off-the-shelf cell therapies for treating cancer and autoimmune diseases. The company focuses on creating allogeneic chimeric antigen receptor (CAR) engineered natural killer T (NKT) cell therapies, which use NKT cells to target and destroy cancer cells or modulate the immune response in autoimmune conditions. This approach aims to increase treatment accessibility and scalability by utilizing non-patient-specific cells.

heXem bio specializes in recording solutions for the early development of humans for longevity.

Zhenshi Medical is a medical device company that specializes in lung puncture medical robots for diagnosing and treating lung cancer.

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Founded in 2015, GlowDx specializes in developing point-of-care diagnostic platforms. Utilizing novel molecular technology and machine learning, the company aims to democratize access to diagnostics globally, enabling timely detection of infectious diseases and reducing disease burden.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Calder Biosciences engineers next-generation vaccines using its proprietary 3D-Vaxlock technology. This platform generates molecular staples that lock vaccines into their most potent shape, enhancing immune response and stability. Calder's initial focus is on developing a universal flu vaccine and an RSV vaccine for the elderly. Their vaccines aim to protect against life-threatening diseases with improved safety, efficacy, and durability, reducing healthcare burden globally.

Cell BioEngines is a clinical-stage biotechnology company specializing in developing 'off-the-shelf' stem cell therapies as drugs for treating human diseases. The company's core platform enables the production of high-quality, pure, and potent cell products at scale using a universal blood stem cell-derived technology.

Proton Intelligence develops a wearable device that monitors potassium levels in real-time via interstitial fluid, closely correlated to blood. This enables clinicians and patients to manage medications and diets effectively for improved heart and kidney care, particularly targeting hyperkalemia in chronic kidney disease patients with co-morbidities.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Avisa Myko is a biotechnology company based in San Francisco, California. It specializes in the production of melanin, a natural pigment with applications in cosmetics, biomedicine, organic semiconductors, biosensors, and latex products. The company's patented technology enables large-scale production of soluble, affordable melanin, offering protection against ionizing radiation and contributing to better health and environmental sustainability.

XN Health is a medical device company founded in 2021 and based in Texas, USA. The company focuses on developing innovative healthcare solutions to assist mechanically ventilated patients in weaning off ventilators more efficiently. Its primary product utilizes phrenic nerve stimulation to induce diaphragm contractions, thereby mitigating the risks of diaphragm dysfunction associated with prolonged mechanical ventilation. By enhancing the weaning process, XN Health aims to improve patient outcomes and facilitate recovery in critical care settings.

Reactosome is a biotechnology company that develops synthetic nuclei for gene therapy. Its core product, a synthetic nucleus, operates continuously within cells, mimicking the natural nucleus to affect multiple genes simultaneously. This approach aims to enhance the safety and longevity of gene expression, thereby enabling the development of treatments for complex diseases such as cancer and age-related disorders.

Chronus Health develops a portable diagnostic device for delivering point-of-care lab results in minutes. Its device enables real-time diagnosis at the point-of-care, improving time to care and patient outcomes.

Founded in 2011, Verdex Technologies specializes in the mass production of non-toxic nanofibers using proprietary green technology. The company designs, patents, and licenses equipment for filtration and biomedical purposes, creating advanced performance nanofiber materials for various applications such as engine filters, liquid filters, industrial air filters, waterproof textiles, medical packaging, and face masks.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Lura Health develops a non-invasive continuous health monitoring platform that uses saliva as a diagnostic fluid. The company integrates micro-sensors into orthodontic devices such as retainers, aligners, and brackets to continuously measure saliva analytes and securely transmit data to a smartphone app, enabling users to monitor oral health metrics and potentially support broader chronic disease management. Target markets include heart disease, chronic kidney disease, diabetes, and tooth decay. Founded in 2017, the company is based in Cambridge, Massachusetts.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Hypercell Technologies develops tools to control infectious diseases in animals, including diagnostics and monoclonal antibodies designed to curb viruses in production animal reservoirs. The company employs molecular biology to create rapid, on-farm diagnostics that enable veterinarians to detect infections quickly and implement preventive measures. By focusing on proactive control of viruses in animal populations, Hypercell aims to reduce the emergence of diseases that could threaten human health and improve animal health management across production settings.

Founded in 2018, Rizlab Health specializes in developing compact blood diagnostic devices. Their flagship product is CytoTracker, a pocket-sized, wireless analyzer powered by artificial intelligence, designed to deliver rapid and affordable white blood cell count analysis.

BioAesthetics develops tissue-engineered nipple-areolar complex grafts to support breast reconstruction after mastectomy. The graft is designed as a scaffold for the patient's own cells to populate and regenerate the nipple and areola during reconstruction, aiming to improve cosmetic and reconstructive outcomes. The company originated as a Tulane University spin-out and was founded in 2015.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Calder Biosciences engineers next-generation vaccines using its proprietary 3D-Vaxlock technology. This platform generates molecular staples that lock vaccines into their most potent shape, enhancing immune response and stability. Calder's initial focus is on developing a universal flu vaccine and an RSV vaccine for the elderly. Their vaccines aim to protect against life-threatening diseases with improved safety, efficacy, and durability, reducing healthcare burden globally.

Cell BioEngines is a clinical-stage biotechnology company specializing in developing 'off-the-shelf' stem cell therapies as drugs for treating human diseases. The company's core platform enables the production of high-quality, pure, and potent cell products at scale using a universal blood stem cell-derived technology.

Avisa Myko is a biotechnology company based in San Francisco, California. It specializes in the production of melanin, a natural pigment with applications in cosmetics, biomedicine, organic semiconductors, biosensors, and latex products. The company's patented technology enables large-scale production of soluble, affordable melanin, offering protection against ionizing radiation and contributing to better health and environmental sustainability.

Founded in 2011, Verdex Technologies specializes in the mass production of non-toxic nanofibers using proprietary green technology. The company designs, patents, and licenses equipment for filtration and biomedical purposes, creating advanced performance nanofiber materials for various applications such as engine filters, liquid filters, industrial air filters, waterproof textiles, medical packaging, and face masks.

TippingPoint Biosciences is developing therapeutics that target abnormal DNA packaging states in diseases such as cancer.

Founded in 2019, Karma Biotechnologies is a Los Angeles-based company dedicated to developing therapies for autoimmune diseases, allergies, and food sensitivities. It specializes in antigen-specific immunotherapies using lipid nanoparticle engineering.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Pear Bio is a biotechnology company based in Boston and London. It develops precision medicine-guided therapeutics for hard-to-treat cancers using AI. The company analyzes tumor biopsies and blood to identify new targets, then tests drug candidates directly on patient samples using its proprietary immune-microtumor system.

Care Constitution operates a telehealth platform that facilitates remote medical consultations. It uses AI to analyze sound and images during virtual appointments, generating real-time clinical data and automated assessments for healthcare providers.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

AuraSense employs AI and automation to convert subjective neurological examinations into objective, quantifiable data. This enables neurologists to accurately assess their patients' cognitive and physical health.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Kolibri specializes in developing innovative bioreactors that significantly enhance cell culture yields while reducing production costs. Their proprietary platform, combining cutting-edge acoustics and biology techniques, aims to make cell and gene therapies more accessible and affordable.

Cell BioEngines is a clinical-stage biotechnology company specializing in developing 'off-the-shelf' stem cell therapies as drugs for treating human diseases. The company's core platform enables the production of high-quality, pure, and potent cell products at scale using a universal blood stem cell-derived technology.

Pear Bio is a biotechnology company based in Boston and London. It develops precision medicine-guided therapeutics for hard-to-treat cancers using AI. The company analyzes tumor biopsies and blood to identify new targets, then tests drug candidates directly on patient samples using its proprietary immune-microtumor system.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.

Midoconline is a technology company focused on improving quality of life through medical and wellness services. It has developed a telehealth platform that facilitates video-based consultations between patients and healthcare professionals. Through its mobile application, Midoconline enables users to connect with doctors for remote consultations regarding non-emergency medical issues, thereby enhancing access to healthcare services.

QV Bioelectronics develops an innovative electric field therapy implant, GRACE, designed to extend the lives of brain tumor patients while maintaining their quality of life. This first-of-its-kind device targets glioblastoma, a cancer with poor outcomes, by slowing tumor growth and sparing healthy tissue.

Metabolomic Diagnostics Ltd., established in 2011 and based in Little Island, Ireland, is a medical diagnostics company focused on early disease detection. It specializes in developing a mass spectrometry-based diagnostic platform that analyzes multiple biomarkers simultaneously, enabling predictive diagnosis of complex diseases. The company's primary application is a blood test for predicting the risk of pre-eclampsia, a pregnancy complication characterized by high blood pressure and protein in the urine, which can lead to restricted blood supply to the fetus. By identifying diagnostic biomarker panels and translating them into clinical assays, Metabolomic Diagnostics aims to improve pregnancy outcomes through early intervention.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Bisu is a health technology company that offers a home health lab designed to enhance personal well-being through urine and saliva tests. Its devices monitor various health metrics, including dietary health, fat metabolism, and hydration levels, providing users with daily feedback on electrolytes, hydration, pH, ketones, and uric acid via a mobile application. This functionality enables individuals to track burned body fat, maintain metabolic health, achieve optimal ketosis, and improve physical endurance. Bisu has received recognition for its innovation, having been awarded by prestigious organizations such as Johnson & Johnson Innovation and MedTech Innovator, and it gained further acclaim at CES 2020 with the IHS Markit Innovation Award.

Free to Feed is a company focused on enhancing breastfeeding experiences by providing solutions for detecting food allergens in breast milk. It offers an innovative over-the-counter allergen test that empowers breastfeeding mothers to identify various food proteins in their milk, which is crucial for those concerned about potential infant food allergies or intolerances. The company’s patented testing kits, combined with a mobile application, allow mothers to document the presence of allergens, the timing of milk expression, and any symptoms their infants may exhibit. This comprehensive data collection aids medical professionals in diagnosing and managing food allergies effectively. With a growing recognition of the importance of early allergen introduction to mitigate future allergies, Free to Feed supports parents in navigating these complexities with tailored counseling and technology, ensuring they can confidently meet their breastfeeding goals while safeguarding their infants' health.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

ChektAhora is a Latin American company specializing in at-home testing kits for sexually transmitted infections (STIs). Their platform offers confidential, convenient, and pain-free testing solutions, utilizing PCR tests to identify STIs and other infectious diseases like influenza and COVID-19. The company aims to provide accessible healthcare services directly to customers' homes or offices.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Spindle Biotech Inc., founded in 2017 and headquartered in Toronto, Canada, specializes in the development and commercialization of synthetic RNA technologies. The company focuses on a proprietary RNA polymerase that enhances large-scale mRNA vaccine production, reflecting the increasing relevance of synthetic RNA in biotechnological applications. Leveraging advances in mRNA technology, Spindle Biotech aims to facilitate high-throughput ribonucleoprotein (RNP)-based CRISPR and RNA screening. Utilizing advanced enzymes and microfluidic technology, it creates RNA arrays with high fidelity, which are vital for gene-editing and drug discovery initiatives. Through these innovations, Spindle Biotech seeks to support biotechnology companies in harnessing the transformative potential of synthetic RNA.

Founded in 2011, Verdex Technologies specializes in the mass production of non-toxic nanofibers using proprietary green technology. The company designs, patents, and licenses equipment for filtration and biomedical purposes, creating advanced performance nanofiber materials for various applications such as engine filters, liquid filters, industrial air filters, waterproof textiles, medical packaging, and face masks.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Proton Intelligence develops a wearable device that monitors potassium levels in real-time via interstitial fluid, closely correlated to blood. This enables clinicians and patients to manage medications and diets effectively for improved heart and kidney care, particularly targeting hyperkalemia in chronic kidney disease patients with co-morbidities.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Filtricine is a Santa Clara, California-based biotechnology company focused on cancer therapy through targeted nutrient depletion. The company develops approaches that remove nutrients critical to cancer cell growth, enabling exploitation of cancer-specific metabolic dependencies without traditional drug substances. Through a nutrient modulation platform, Filtricine aims to identify metabolic vulnerabilities in cancers and apply strategies to deprive tumor cells of essential nutrients, potentially slowing or stopping disease progression. Founded in 2017, Filtricine operates as a clinical-stage, venture-backed biotechnology company dedicated to developing therapies that spare normal cells while targeting cancer metabolism.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Founded in 2014, Machine Medicine Technologies develops an AI-powered platform for objective measurement of movement disorders like Parkinson's disease. Using computer vision and pose estimation techniques, it tracks patient movements to provide secure, accessible, and affordable metrics for researchers and healthcare providers.

Chronos DX is a biotechnology research company based in London, Germany, specializing in drug development and in vitro diagnostics within the healthcare sector. The company is known for its innovative bioassay technology, which is designed for diagnostics, drug screening, and development. Chronos DX focuses on creating high-performance, low-cost, and scalable technology capable of detecting a variety of biomarkers, including cell-free DNA, micro proteins, exosomes, and metabolites. This technology provides medical professionals with a platform for in-line and in vivo monitoring of biomarkers, enhancing the capabilities of diagnostics and drug development in medical practice.

Founded in 2015, GlowDx specializes in developing point-of-care diagnostic platforms. Utilizing novel molecular technology and machine learning, the company aims to democratize access to diagnostics globally, enabling timely detection of infectious diseases and reducing disease burden.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

QV Bioelectronics develops an innovative electric field therapy implant, GRACE, designed to extend the lives of brain tumor patients while maintaining their quality of life. This first-of-its-kind device targets glioblastoma, a cancer with poor outcomes, by slowing tumor growth and sparing healthy tissue.

Developer of a portable diagnostic biosensor device for accurate pathogen detection. The device enables early diagnosis and treatment, reducing infection spread and improving patient outcomes.

AnimalBiome specializes in personalized pet nutrition, focusing on improving gut health for dogs and cats through microbiome science. The company offers microbiome tests to analyze pets' gut bacteria and provides tailored restorative supplements sourced from healthy animals to balance the microbiome.

Founded in August 2019, Portable Diagnostic Systems develops a microfluidics-based drug testing platform for law enforcement. This platform uses salivary diagnostics, antibody engineering, and micro-fluidics to accurately screen drugs from a small saliva sample collected at roadside stops, aiming to reduce false positives and enhance traffic stop efficiency.

Founded in 2019, Kalia Health is a biotechnology company based in Chapel Hill, North Carolina. It develops affordable and accessible home-based early detection tests to improve maternal health outcomes.

Metabolomic Diagnostics Ltd., established in 2011 and based in Little Island, Ireland, is a medical diagnostics company focused on early disease detection. It specializes in developing a mass spectrometry-based diagnostic platform that analyzes multiple biomarkers simultaneously, enabling predictive diagnosis of complex diseases. The company's primary application is a blood test for predicting the risk of pre-eclampsia, a pregnancy complication characterized by high blood pressure and protein in the urine, which can lead to restricted blood supply to the fetus. By identifying diagnostic biomarker panels and translating them into clinical assays, Metabolomic Diagnostics aims to improve pregnancy outcomes through early intervention.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Founded in 2020, Conan MedTech specializes in developing rapid point-of-care diagnostic tests for concussions. Its innovative technology enables sports medicine professionals and coaches to make informed decisions on the sideline during games, revolutionizing mild traumatic brain injury diagnosis.

Founded in 2020, Conan MedTech specializes in developing rapid point-of-care diagnostic tests for concussions. Its innovative technology enables sports medicine professionals and coaches to make informed decisions on the sideline during games, revolutionizing mild traumatic brain injury diagnosis.

Founded in 2019, Kalia Health is a biotechnology company based in Chapel Hill, North Carolina. It develops affordable and accessible home-based early detection tests to improve maternal health outcomes.

Avisa Myko is a biotechnology company based in San Francisco, California. It specializes in the production of melanin, a natural pigment with applications in cosmetics, biomedicine, organic semiconductors, biosensors, and latex products. The company's patented technology enables large-scale production of soluble, affordable melanin, offering protection against ionizing radiation and contributing to better health and environmental sustainability.

ArgenTAG is a biotechnology company specializing in genomic sequencing. It offers a proprietary technology designed to reduce the cost of long-read sequencing applications.

ArgenTAG is a biotechnology company specializing in genomic sequencing. It offers a proprietary technology designed to reduce the cost of long-read sequencing applications.

Free to Feed is a company focused on enhancing breastfeeding experiences by providing solutions for detecting food allergens in breast milk. It offers an innovative over-the-counter allergen test that empowers breastfeeding mothers to identify various food proteins in their milk, which is crucial for those concerned about potential infant food allergies or intolerances. The company’s patented testing kits, combined with a mobile application, allow mothers to document the presence of allergens, the timing of milk expression, and any symptoms their infants may exhibit. This comprehensive data collection aids medical professionals in diagnosing and managing food allergies effectively. With a growing recognition of the importance of early allergen introduction to mitigate future allergies, Free to Feed supports parents in navigating these complexities with tailored counseling and technology, ensuring they can confidently meet their breastfeeding goals while safeguarding their infants' health.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Inso Biosciences is an early-stage biotechnology company that develops microfluidic hardware platforms for genomic sample handling. The company's patented microfluidic technology enables high-efficiency processing of cellular material and the separation and isolation of cellular components, supporting genomic analysis and DNA sequencing workflows. Its platform aims to improve long-read DNA extraction, multiomic sample processing, and pathogen surveillance, enabling healthcare and biotech organizations to perform biological sample preparation with greater efficiency and accuracy.

Chronus Health develops a portable diagnostic device for delivering point-of-care lab results in minutes. Its device enables real-time diagnosis at the point-of-care, improving time to care and patient outcomes.

VemiCo is a biotechnology company focused on extending healthy living by addressing the aging process. The company leverages artificial intelligence and synthetic biology to discover and advance promising molecules derived from gut microbial DNA. By harnessing the potential of microbiomes, VemiCo aims to enhance gut health and overall well-being, offering innovative solutions for medical professionals in the health sector.